Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 1, 2000, Pages 29-42

  Hein, David W ^a   Doll, Mark A ^a   Fretland, Adrian J ^a   Leff, Matthew A ^a   Webb, Stephanie J ^a   Xiao, Gong H ^a   Devanaboyina, Udaya Sankar ^a   Nangju, Norma A ^a   Feng, Yi ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; BLADDER CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; COLORECTAL CANCER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MOLECULAR GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL MARKERS; CARCINOGENS; COLONIC NEOPLASMS; EPIDEMIOLOGY, MOLECULAR; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; ISOENZYMES; MOLECULAR BIOLOGY; PHENOTYPE; POLYMORPHISM, GENETIC; RECTAL NEOPLASMS; RISK FACTORS; TERMINOLOGY; URINARY BLADDER NEOPLASMS;

EID: 0033960051     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (210)

1. Weber, W. W., and Hein, D. W. N-Acetylation pharmacogenetics. Pharmacol. Rev., 37: 25-79, 1985.
2. Weber, W. W. The Acetylator Genes and Drug Response. New York: Oxford University Press, 1987.
3. Hein, D. W. Aeetylator genotype and arylamine-induced carcinogenesis. Biochim. Biophys. Acta, 948: 37-66, 1988.
4. Evans, D. A. P. N-Acetyltransferase. Pharmacol. Ther., 42: 157-234, 1989.
5. Evans, D. A. P. Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics. Cambridge, UK: Cambridge University Press, 1993.
6. Grant, D. M., Hughes, N. C., Janezic, S. A., Goodfellow, G. H., Chen, H. J., Gaedigk, A., Yu, V. L., and Grewal, R. Human acetyltransferase polymorphisms. Mutat. Res., 376: 61-70, 1997.
7. Hein, D. W., Doll, M. A., Fretland, A. J., Gray, K., Deitz, A. C., Feng, Y., Jiang, W., Rustan, T. D., Satran, S., and Wilkie, T. R. Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. Mutat. Res., 376: 101-106, 1997.
8. Lang, N. P. Acetylation as an indicator of risk. Environ. Health Perspect., 105: 763-766, 1997.
9. Meyer, U. A., and Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol., 37: 269-296, 1997.
10. Weber, W. W. Pharmacogenetics. New York: Oxford University Press, 1997.
11. Cascorbi, I., Brockmoller, J., Mrozikiewicz, P. M., Muller, A., and Roots, I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev., 31: 489-502, 1999.
12. Hulla, J. E., Miller, M. S., Taylor, J. A., Hein, D. W., Furlong, C. E., Omiecinski, C. J., and Kunkel, T. A. Symposium overview: the role of genetic polymorphisms and repair deficiencies in environmental disease. Toxicol. Sci., 47: 135-143, 1999.
13. Wormhoudt, L. W., Commandeur, J. N. M., and Vermeulen, N. P. E. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol., 29: 59-124, 1999.
14. Hein, D. W. N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett., in press.
15. Hughes, H. B., Biehl, J. P., Jones, A. P., and Schmidt, L. H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am. Rev. Res. Dis., 70: 266-273, 1954.
16. Evans, D. A. P., and White, T. A. Human acetylation polymorphism. J. Lab. Clin. Med., 63: 394-403, 1964.
17. Weber, W. W., and Hein, D. W. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet., 4: 401-422, 1979.
18. Jenne, J. W. Partial purification and properties of the isoniazid transacetylase in human liver: its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Investig., 44: 1992-2002, 1965.
19. Hein, D. W., Kirlin, W. G., Ferguson, R. J., and Weber, W. W. Biochemical investigation of the basis for the genetic N-acetylation polymorphism in the inbred hamster. J. Pharmacol. Exp. Ther., 234: 358-364, 1985.
20. Smith, T. J., and Hanna, P. E. N-Acetyltransferase multiplicity and bioactivation of N-arylhydroxamic acids by hamster hepatic and intestinal enzymes. Carcinogenesis (Lond.), 7: 697-702, 1986.
21. Ozawa, S., Abu-Zeid, M., Kawakubo, Y., Toyama, S., Yamazoe, Y., and Kato, R. Monomorphic and polymorphic isozymes of arylamine N-acetyltransferases in hamster liver: purification of the isozymes and genetic basis of N-acetylation polymorphism. Carcinogenesis (Lond.), 11: 2137-2144, 1990.
22. Grant, D. M., Beer, M., Blum, M., and Meyer, U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol., 39: 184-191, 1991.
23. Grant, D. M., Morike, K., Eichelbaum, M., and Meyer, U. A. Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin. Investig., 85: 968-972, 1990.
24. Deguchi, T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J. Biol. Chem., 267: 18140-18147, 1992.
25. Vatsis, K. P., and Weber, W. W. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch. Biochem. Biophys., 301: 71-76, 1993.
26. Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J-M., Price-Evans, D. A., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U. A., Relling, M. V., Sim, E., Suzuki, T., and Yamazoe, Y. Nomenclature for N-acetyltransferases. Pharmacogenetics, 5: 1-17, 1995.
27. Minchin, R. F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J., 307: 1-3, 1995.
28. Ward, A., Summer, M. J., and Sim, E. Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coll and characterization of its potential role in folate metabolism. Biochem. Pharmacol., 49: 1759-1767, 1995.
29. Layton, D. W., Bogen, K. T., Knize, M. G., Hatch, F. T., Johnson, V. M., and Felton, J. S. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis (Lond.), 16: 39-52, 1995.
30. 68 in the catalytic mechanism of polymorphic human NAT2. J. Biol. Chem. 267: 7381-7385, 1992.
31. Hein, D. W., Doll, M. A., Rustan, T. D., and Ferguson, R. J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res., 55: 3531-3536, 1995.
32. Hein, D. W., Flammang, T. J., Kirlin, W. G., Trinidad, A., and Ogolla, F. Acetylator genotype dependent metabolic activation of carcinogenic N-hydroxyarylamines by S-acetyl coenzyme A-dependent enzymes of inbred hamster tissue cytosols: relationship to arylamine N-acetyltransferase. Carcinogenesis (Lond.), 8: 1767-1774, 1987.
33. Ogolla, F., Ferguson, R. J., Kirlin, W. G., Trinidad, A., Andrews, A. F., Mpezo, M., and Hein, D. W. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxy-arylamine O-acetyltransferase in Syrian inbred hamster intestine and colon: identity with the hepatic acetylation polymorphism. Drug Metab. Dispos., 18: 680-685, 1990.
34. Turesky, R. J., Lang, N. P., Butler, M. A., Teitel, C. H., and Kadlubar, F. F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis (Lond.), 12: 1839-1845, 1991.
35. Minchin, R. F., Reeves, P. T., Teitel, C. H., McManus, M. E., Mojarrabi, B., Ilett, K. F., and Kadlubar, F. F. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem. Biophys. Res. Commun., 185: 839-844, 1992.
36. Hem, D. W., Doll, M. A., Rustan, T. D., Gray, K., Feng, Y., Ferguson, R. J., and Grant, D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis (Lond.), 14: 1633-1638, 1993.
37. Hein, D. W., Rustan, T. D., Ferguson, R. J., Doll, M. A., and Gray, K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch. Toxicol., 68: 129-133, 1994.
38. Blum, M., Demierre, A., Grant, D. M., Heim, M., and Meyer, U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA, 88: 5237-5241, 1991.
39. Vatsis, K. P., Martell, K. J., and Weber, W. W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. USA, 88: 6333-6337, 1991.
40. Blum, M., Grant, D. M., McBride, W., Heim, M., and Meyer, U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol., 9: 193-203, 1990.
41. Hickman, D., Risch, A., Buckle, V., Spurr, N., Jeremiah, S. J., McCarthy, A., and Sim, E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J., 297; 441-445, 1994.
42. Matsus, N., Thygesen, P., Stacey, M., Risch, A., and Sim, E. Mapping AAC1, AAC2, and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet. Cell Genet., 77: 290-295, 1997.
43. Kelly, S. L., and Sim, E. Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem. J., 302: 347-353, 1994.
44. Fretland, A. J., Doll, M. A., Gray, K., Feng, Y., and Hein, D. W. Cloning, sequencing, and functional expression of NAT1, NAT2, and NAT3 derived from C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol. Appl. Pharmacol., 142: 360-366, 1997.
45. Ebisawa, T., and Deguchi, T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem. Biophys. Res. Commun., 177: 1252-1257, 1991.
46. Ishibe, N., Wiencke, J. K., Zuo, Z-F., McMillan, A., Spitz, M., and Kelsey, K. T. Polymorphisms in the N-acetyltransferase 1 (NAT1) gene and lung cancer risk in a minority population. Biomarkers, 3: 219-226, 1998.
47. Zheng, W., Deitz, A. C., Campbell, D. R., Wen, W-Q., Cerhan, J. R., Sellers, T. A., Folsom, A. R., and Hein, D. W. N-Acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 8: 233-239, 1999.
48. Probst-Hensch, N. M., Haile, R. W., Li, D. W., Sakamota, G. T., Louie, A. D., Lin, B. K., Frankl, H. D., Lee, E. R., and Lin, H. J. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis (Lond.), 17: 2125-2129, 1996.
49. Ohsako, S., and Deguchi, T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Biol. Chem., 265: 4630-4634, 1990.
50. Doll, M. A., Jiang, W., Deitz, A. C., Rustan, T. D., and Hein, D. W. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem. Biophys. Res. Commun., 233: 584-591, 1997.
51. Hughes, N. C., Janezic, S. A., McQueen, K. L., Jewett, M. A. S., Castranio, T., Bell, D. A., and Grant, D. M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics, 8: 55-66, 1998.
52. Payton, M. A., and Sim, E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem. Pharmacol., 55: 361-366, 1998.
53. Hubbard, A., Moyes, C., Wyllie, A. H., Smith, C. A. D., and Harrison, D. J. N-Acetyltransferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. Br. J. Cancer, 77: 913-916, 1998.
54. de Leon, J. H., Vatsis, K. P., and Weber, W. W. Catalytic activities of human N-acetyltransferase (NAT1) variants expressed in COS-1 cells. FASEB J., 10: A456, 1996.
55. Butcher, N. J., Ilett, K. F., and Minchin, R. F. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics, 8: 67-72, 1998.
56. Lin, H. J., Probst-Hensch, N. M., Hughes, N. C., Sakamoto, G. T., Louie, A. D., Kau, I. H., Lin, B. K., Lee, D. B., Lin, J. Frankl, H. D., Lee, E. R., Hardy, S., Grant, D. M., and Haile, R. W. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics, 8: 269-281, 1998.
57. Deitz, A. C., Doll, M. A., Fretland, A. J., and Hein, D. W. Homo sapiens N-acetyltransferase NAT1 (allele NAT1*18A) gene, complete cds. GenBank AF032677, 1997.
58. Deitz, A. C., Doll, M. A., Fretland, A. J., and Hein, D. W. Homo sapiens N-acetyltransferase NAT1 (allele NAT1*18B) gene, complete cds. GenBank AF032678, 1997.
59. Deitz, A. C., Fretland, A. J., Leff, M. A., and Hein, D. W. Homo sapiens N-acetyltransferase-1 (NAT1) gene, NAT1*26A allele, complete cds. GenBank AF071552, 1998.
60. Deitz, A. C., Fretland, A. J., Left M. A., Doll, M. A., and Hein, D. W. Homo sapiens N-acetyltransferase-1 (NAT1) gene, NAT1*26B allele, complete cds. GenBank AF067408, 1998.
61. Lo-Guidice, J-M., Marez, D., Barat, F., Spire, C., Chevalier, D., and Broly, F. Human N-acetyltransferase 1 (NAT1) gene, NAT1*28 allele. GenBank AF082904, 1999.
62. Lo-Guidice, J-M., Marez, D., Barat, F., Spire, C., Chevalier, D., and Broly, F. Human N-acetyltransferase 1 (NAT1) gene, NAT1*29 allele. GenBank AF082903, 1999.
63. Grant, D. M., Blum, M., Demierre, A., and Meyer, U. A. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res., 17: 3978, 1989.
64. Hickman, D., and Sim, E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem. Pharmacol., 42: 1007-1014, 1992.
65. Hickman, D., Risch, A., Camilleri, J. P., and Sim, E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics, 2: 217-226, 1992.
66. Lin, J. J., Han, C-Y., Link B. K., and Hardy, S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet., 52: 827-834, 1993.
67. Cascorbi, I., Drakoulis, N., Brockmoller, J., Mauer, A. Sperling, K., and Roots, I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet., 57: 581-592, 1995.
68. Abe, M., Deguchi, T., and Suzuki, T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem. Biophys. Res. Commun., 191: 811-816, 1993.
69. Ferguson, R. J., Doll, M. A., Rustan, T. D., Gray, K., and Hein, D. W. Cloning, expression, and functional characterization of two mutant (NAT2 191 and NAT2 341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab. Dispos., 22; 371-376, 1994.
70. Martinez, C., Agundez, J. A. G., Olivera, M., Martin, R., Ladero, J. M., and Benitez, J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics, 5: 207-214, 1995.
71. Agundez, J. A. G., Olivera, M., Ladero, J. M., Lescure-Rodriguez, A., Ledesma, M. C., Diaz-Rubio, M., Meyer, U. A., and Benitez, J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics, 6: 501-512, 1996.
72. Agundez, J. A. G., Olivera, M., Martinez, C., Ladero, J. M., and Benitez, J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics, 6: 423-428, 1996.
73. Leff, M. A., Fretland, A. J., Doll, M. A., and Hein, D. W. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem., 274: 34519-34522, 1999.
74. Woolhouse, N. M., Qureshi, M. M., and Bayoumi, R. A. A new mutation C759T in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics, 7: 83-84, 1997.
75. Agundez, J. A., Martinez, C., Olivera, M., Ledesma, M. C., Ladero, J. M., and Benitez, J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin. Pharmacol. Ther., 56: 202-209, 1994.
76. Cascorbi, I., Brockmoller, J., Bauer, S., Reum, T., and Roots, I. NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics, 6: 257-259, 1996.
77. Bell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubaker, L. H., Kadlubar, F. F., and Lucier, G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis (Lond.), 14: 1689-1692, 1993.
78. Delomenie, C., Sica, L., Grant, D. M., Krishnamoorthy, R., and Dupret, J-M. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics, 6: 177-185, 1996.
79. Lin, H. J., Han, C-Y., Lin, B. K., and Hardy, S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics, 4: 125-134, 1994.
80. Nebert, D. W., Ingelman-Sundberg, M., and Daly, A. K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev., 31: 467-487, 1999.
81. Ilett, K. F., Kadlubar, F. F., and Minchin, R. F. 1998 Meeting on arylamine N-acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metab. Dispos., 27: 957-959, 1999.
82. Hein, D. W., Grant, D. M., and Sim, E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics, in press, 2000.
83. Shen, L. X., Basilion, J. P., and Stanton, V. P., Jr. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci. USA, 96: 7871-7876, 1999.
84. Cascorbi, I., and Roots, I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics. 9: 123-127, 1999.
85. Rothman, N., Stewart, W. F., Caporaso, N. E., and Hayes, R. B. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol. Biomark. Prev., 2: 299-303, 1993.
86. Rothman, N., Caporaso, N. E., Wacholder, S., Garcia-Closas, M., Lubin, J. H., Marcus, P., Hoover, R. N., and Fraumeni, J. F., Jr. Evaluation of interactions between environmental exposures and common genetic polymorphisms: a population-based epidemiologic perspective. Proc. Am. Assoc. Cancer Res., 40: 762-763, 1999.
87. Blum, M., Grant, D. M., Demierre, A., and Meyer, U. A. N-Acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc. Natl. Acad. Sci. USA, 86: 9554-9557, 1989.
88. Ferguson, R. J., Doll, M. A., Rustan, T. D., Baumstark, B. R., and Hein, D. W. Polymorphic arylamine N-acetyltransferase encoding gene (NAT2) from homozygous rapid and slow acetylator congenic Syrian hamsters. Gene (Amst.), 740: 247-249, 1994.
89. Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Yamazoe, Y., and Kato, R. Primary structure and molecular basis of polymorphic appearance of an acetyltransferase (AT-II) in hamsters. Pharmacogenetics. 4: 91-100, 1994.
90. Ferguson, R. J., Doll, M. A., Rustan, T. D., and Hein, D. W. Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyltransferase encoding genes of the Syrian hamster. Pharmacogenetics, 6: 55-66, 1996.
91. Martell, J. J., Vatsis, K. P., and Weber, W. W. Molecular genetic basis of rapid and slow acetylator phenotype in mice. Mol. Pharmacol., 40: 218-227, 1991.
92. de Leon, J. H., Martell, K. J., Vatsis, K. P., and Weber, W. W. Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). Drug Metab. Dispos., 23: 1354-1361, 1995.
93. Ferguson, R. J., Doll, M. A., Rustan, T. D., Baumstark, B. R., and Hein, D. W. Syrian hamster monomorphic N-acetyltransferase (NAT1) alleles: amplification, cloning, sequencing, and expression in E. coli. Pharmacogenetics, 4: 82-90, 1994.
94. Hein, D. W., Ferguson, R. J., Doll, M. A., Rustan, T. D., and Gray, K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant human wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet., 3: 729-734, 1994.
95. Dupret, J-M., Goodfellow, G. H., Janezic, S. A., and Grant, D. M. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2: functional analysis of NAT1/NAT2 protein chimeras expressed in E. coli. J. Biol. Chem., 269: 26830-26835, 1994.
96. Hickman, D., Palamanda, J. R., Unadkat, J. D., and Sim, E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem. Pharmacol., 50: 697-703, 1995.
97. 64 in the catalytic function of the human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem. J., 323: 207-215, 1997.
98. O'Neil, W. M., Drobitch, R. K., MacArthur, R. D., Farrough, M. J., Doll, M. A., Fretland, A. J., Hein, D. W., Crane, L. R., and Svensson, C. R. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics, in press, 2000.
99. Fretland, A. J., Leff, M. A., Doll, M. A., and Hein, D. W. Functional analysis of single nucleotide substitutions in the human NAT2 gene in a yeast expression system. Proc. Am. Assoc. Cancer Res., 40: 469, 1999.
100. Cartwright, R. A., Glashan, R. W., Rogers, H. J., Ahmad, R. A., Barham-Hall, D., Higgins, E., and Kahn, M. A role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2: 842-846, 1982.
101. Vesell, E., and Gaylor, D. Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. Pharmacogenetics, 5: 18-23, 1995.
102. Grant, D. M., Tang, B. K., and Kalow, W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol., 17: 43-50, 1984.
103. Cribb, A. E., Isbrucker, R., Levatte, T., Tsui, B., Gillespie, C. T., and Renton, K. W. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlated with a marker of systemic NAT1 activity. Pharmacogenetics, 4: 166-170, 1994.
104. Lorenzo, B., and Reidenberg, M. M. Potential artifacts in the use of caffeine to determine acetylation phenotype. Br. J. Clin. Pharmacol., 28: 207-208, 1989.
105. Leyland-Jones, B., Banerjee, K., Lang, N., and Wong, P. A reliable method for NAT2 phenotyping by ELISA. Proc. Am. Assoc. Cancer Res., 40: 53, 1999.
106. Hein, D. W., Doll, M. A., Rustan, T. D., Gray, K., Ferguson, R. J., and Feng, Y. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Toxicol. Appl. Pharmacol., 124: 16-24, 1994.
107. Hein, D. W., Rustan, T. D., Bucher, K. D., and Miller, L. S. Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus. J. Pharmacol. Exp. Ther., 259: 699-704, 1991.
108. Hein, D. W., Doll, M. A., Gray, K., Rustan, T. D., and Ferguson, R. J. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res., 53: 509-514, 1993.
109. Minchin, R. F., Butcher, N. J., and Pope, C. Characterization of the human N-acetyltransferase type 1 gene promotor: identification of ATCATTT repeats flanking an AP-1 like motif in the minimum promotor sequence. In: Proceedings of the First International Workshop on Arylamine N-Acetyltransferases, p. 4. Cairns, Australia: , 1998.
110. Butcher, N. J., Ilett, K., and Minchin, R. F. Substrate regulation of human arylamine N-acetyltransferase type-1. In: Proceedings of the First International Workshop on Arylamine N-Acetyltransferases, p. 22. Cairns, Australia: , 1998.
111. Estrada-Rodgers, L., Levy, G. N., and Weber, W. W. Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expr., 7: 13-24, 1998.
112. Bell, D. A., Badawi, A. F., Lang, N. P., Ilett, K. F., Kadlubar, F., and Hirvonen, A. Polymorphism in the NAT1 polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue samples. Cancer Res., 55: 5226-5229, 1995.
113. Zenser, R. B., Lakshmi, V. M., Rustan, T. R., Doll, M. A., Deitz, A. C., Davis, B. B., and Hein, D. W. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res., 56: 3941-3947, 1996.
114. Badawi, A. F., Bell, D. A., Hirvonen, A., and Kadlubar, F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res., 55; 5230-5237, 1995.
115. Bell, D. A., Stephens, E., Castranio, T., Umbach, D. M., Watson, M., Deakin, M., Elder, J., Duncan, H., Hendrickse, C., and Strange, R. C. Polyadenylation polymorphism in the N-acetyltransferase gene 1 (NAT1) increases risk of colorectal cancer. Cancer Res., 55: 3537-3542, 1995.
116. Grant, D. M., Hughes, N. C., Janezic, S. A., Sampson, H., Darlington, G., and Jewett, M. A. Acetylation polymorphisms and risk for bladder cancer: a case-control study. In: Proceedings of the First International Workshop on Arylamine N-Acetyltransferases, p. 8. Cairns, Australia: , 1998.
117. Patrianakos, C., and Hoffmann, D. Chemical studies on tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. J. Anal. Toxicol., 3: 150-154, 1979.
118. Manabe, S., Tohyama, K., Wada, O., and Aramaki, T. Detection of a carcinogen, 2-amino-1-methyl-6-phenylimidazo [4:5-b]pyridine (PhIP) in cigarette smoke condensate. Carcinogenesis (Lond.), 12: 1945-1947, 1991.
119. Doll, M. A., Fretland, A. J., Deitz, A. C., and Hein, D. W. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem., 231: 413-420, 1995.
120. Bigler, J., Chen, C., and Potter, J. D. Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay. Biotechniques, 22: 682-690, 1997.
121. Deitz, A. C., Doll, M. A., and Hein, D. W. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal. Biochem., 253: 219-224, 1997.
122. Mrozikiewicz, P. M. Cascorbi, I., Brockmoller, J., and Roots, I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase (NAT2) gene in the Polish population. Clin. Pharmacol. Ther., 59: 376-382, 1996.
123. Lower, G. M., Jr., Nilsson, T., Nelson, C. E., Wolf H., Gamsky, T. E., and Bryan, G. T. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect., 29: 71-79, 1979.
124. Haves, R. B., Bi, W., Rothman, N., Broly, F., Caporaso, N., Feng, P., You, X., Yin, S., Woosley, R. S., and Meyer, U. A. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (Lond.), 14: 675-678, 1993.
125. Risch, A., Wallace, D. M., Bathers, S., and Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet., 4: 231-236, 1995.
126. Brockmoller, J., Cascorbi, I., Kerb, R., and Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1996.
127. Okkels, H., Sigsgaard, T., Wolf, A., and Autrup, H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomark. Prev., 6: 225-231, 1997.
128. Filiadis, I. F., Georgiou, I., Alamanos, Y., Kranas, V., Giannakopoulos, X., and Lolis, D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol., 161: 1672-1675, 1999.
129. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. Genetically based N-acetyltransferase polymorphism and low-level environmental exposure to carcinogens. Nature (Lond.), 369: 154-156, 1994.
130. Yu, M. C., Skipper, P. E., Taghizadeh, K., Tannenbaum, S. R., Chan, K. K., Henderson, B., and Ross, R. K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl. Cancer Inst., 86: 712-716, 1994.
131. Taylor, J. A., Umbach, D. M., Castranio, T., Paulson, D., Robertson, C. Mohler, J. E., and Bell, D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res., 58: 3603-3610, 1998.
132. Katoh, T., Inatomi, H., Yang, M., Kawamato, T., Matsumota, T., and Bell, D. A. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics, 9: 401-404, 1999.
133. Stanley, E. A., Coroneos, E., Cuff, R., Hickman, D., Ward, A., and Sim, E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J. Histochem. Cytochem., 44: 1059-1067, 1996.
134. Kloth, M. T., Gee, R. E., Messing, E. M., and Swaminathan, S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis (Lond.), 15: 2781-2878, 1994.
135. Kirlin, W. G., Trinidad, A., Yerokun, T., Ogolla, F., Ferguson, R. J., Andrews, A. F., Brady, P. K., and Hein, D. W. Polymorphic expression of AcCoA-dependent arylamine N-acetyltransferase and AcCoA-dependent O-acetyltransferase activation of N-hydroxyarylamines by human bladder cytosol. Cancer Res., 49: 2448-2454, 1989.
136. Frederickson, S. M., Hatcher, J. F., Reznikoff, C. A., and Swaminathan, S. Acetyltransferase-mediated metabolic activation of N-hydroxy-4-aminohiphenyl by human urothelial cells. Carcinogenesis (Lond.), 13: 955-961, 1992.
137. Levy, G. N., and Weber, W. W. 2-Aminofluorene-DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. Carcinogenesis (Lond.), 13: 159-164, 1992.
138. Jiang, W., Feng, Y., and Hein, D. W. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol., 156: 187-194, 1999.
139. Feng, Y., Jiang, W., and Hein, D. W. 2-Aminofluorene-DNA adduct levels in tumor-target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol., 141: 248-255, 1996.
140. Feng, Y., Jiang, W., Deitz, A. C., and Hein, D. W. 3,2′-Dimethyl-4-aminobiphenyl-DNA adduct formation in tumor target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol., 140: 315-321, 1996.
141. Hein, D. W., Kirlin, W. G., Yerokun, T., Trinidad, A., and Ogolla, F. Inheritance of acetylator genotype-dependent arylamine N-acetyltransferase in hamster bladder cytosol. Carcinogenesis (Lond.), 8: 647-652, 1987.
142. Hein, D. W., Rustan, T. D., Bucher, K. D., Furman E. J., and Martin, W. J. Extrahepatic expression of the N-acetylation polymorphism towards arylamine carcinogens in tumor target organs of an inbred rat model. J. Pharmacol. Exp. Ther., 258: 232-236, 1991.
143. s slow acctylalor congenic mice. Drug Metab. Dispos., 21: 1057-1063, 1993.
144. Stanley, L. A., Mills, I. G., and Sim, E. Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics, 7: 121-130, 1997.
145. Longuemaux, S., Delomenie, C., Gallou, C., Mejean, A., Vincent-Viry, M. N., Bouvier, R., Droz, D., Krishnamoorthy, R., Galteau, M. M., Junien, C., Beroud, C., and Dupret, J. M. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res., 59: 2903-2908, 1999.
146. Trinidad, A., Hein, D. W., Rustan, T. D., Ferguson, R. J., Miller, L. S., Bucher, K. D., Kirlin, W. G., Ogolla, F., and Andrews, A. F. Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: identity with polymorphic N-hydroxyarylamine O-acetyltransferase. Cancer Res., 50: 7942-7949, 1990.
147. Stillwell, W. G., Kidd, L. C., Wishnok, J. S., Tannenbaum, S. R., and Sinha, R. Urinary excretion of unmetabolized and Phase II conjugates of 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine and 2-amino-3,8-dimethylimidazo [4,5-f] quinoxaline in humans: relationship to cytochrome P4501A2 and N-acetyltransferase activity. Cancer Res., 15: 3457-3464, 1997.
148. Kirlin, W. G., Ogolla, F., Andrews, A. F., Trinidad, A., Ferguson, R. J., Yerokun, T., Mpezo, M., and Hein, D. W. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from noncancer and colorectal cancer patients. Cancer Res., 51: 549-555, 1991.
149. Lang, N. P., Chu, D. Z., Hunter, C. F., Kendall, D. C., Flammang, T. J., and Kadlubar, F. F. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg., 121: 1259-1261, 1986.
150. Ilett, K. F., David, B. M., Demon, P., Caslleden, W. M., and Kwa, R. Acetylator phenotype in colorectal carcinoma. Cancer Res., 47: 1466-1469, 1987.
151. Gil, J. P., and Lechner, M. C. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis (Lond.), 19: 37-41, 1998.
152. Ladero, J. M., Gonzalez, J. F., Benitez, J., Vargas, E., Fernandez, M. J., Baki, W., and Diaz-Rubio, M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res., 51: 2098-2100, 1991.
153. Rodriguez, J. W., Kirlin, W. G., Ferguson, R. J., Doll, M. A., Gray, K., Rustan, T. D., Lee, M. E., Kemp, K., Urso, P., and Hein, D. W. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch. Toxicol., 67: 445-452, 1993.
154. Shibuta, K., Nakashima, T., Abe, M., Mashimo, M., Mori, M., Ueo, H., Akiyoshi, T., Sugimachi, K., and Suzuki, T. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer (Phila.), 74: 3108-3112, 1994.
155. Probst-Hensch, N. M., Haile, R. W., Ingles, S. A., Longnecker, M. P., Han, C. Y., Lin, B. K., Lee, D. B., Sakamota, G. T., Franskl, H. D., Lee, E. R., and Lin, H. J. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res., 55: 2017-2020, 1995.
156. Spun, N. K., Gough, A. C., Chinegwundoh, F. I., and Smith, C. A. D. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin. Chem., 41: 1864-1869, 1995.
157. Hubbard, A. L., Harrison, D. J., Moyes, C., Wyllie, A. H., Cunningham, C., Mannion, E., and Smith, C. A. D. N-Acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut, 41: 229-234, 1997.
158. Lang, N. P., Butler, M. A., Massengell, J., Lawson, M., Stotts, R. C., Hauer-Jensen, M., and Kadlubar, F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomark. Prev., 3: 675-682, 1994.
159. Roberts-Thomson, I. C., Ryan, P., Khoo, K. K., Hart, W. J., McMichael, A. J., and Butler, R. N. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet, 347: 1372-1374, 1996.
160. Welfare, M. R., Cooper, J., Bassendine, M. F., and Daly, A. K. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the northeast of England. Carcinogenesis (Lond.), 18: 1351-1354, 1997.
161. Chen, J., Stampfer, M. J., Hough, H. L., Garcia-Closas, M., Willett, W. C., Hennekens, C. H., Kelsey, K. T., and Hunter, D. J. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res., 58: 3307-3311, 1998.
162. Kampman, E., Slattery, M. L., Bigler, J., Leppert, M., Samowitz, W., Caan, B. J., and Potter, J. D. Meat consumption genetic susceptibility and colon cancer risk: a United States multicenter case-control study. Cancer Epidemiol. Biomark. Prev., 8: 15-24, 1999.
163. Skog, K., Steineck, G., Augustsson, K., and Jugerstad, M. Effect of cooking temperature on the formation of heterocyclic amines in fried meat products and pan residues. Carcinoeenesis (Lond.), 16: 861-867, 1995.
164. DeMarini, D. M., Hastings, S. B., Brooks, L. R., Eischen, B. T., Bell, D. A., Watson, M. A., Felton, J. S., Sandler, R., and Kohlmeiter, L. Pilot study of free and conjugated urinary mutagenicity during consumption of pan-fried meats: possible modulation by cruciferous vegetables, glutathione S-transferase M1, and N-acetyltransferase-2. Mutat. Res., 19: 83-96, 1997.
165. Cascorbi, I., Brockmoller, J., Mrozikiewicz, P. M., Bauer, S., Loddenkemper, R., and Roots, I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res., 56: 3961-3966, 1996.
166. Henning, S., Cascorbi, I., Munchow, B., Jahnke, V., and Roots, I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics, 9: 103-111, 1999.
167. Smelt, V. A., Mardon, H. J., and Sim, E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human N-acetyltransferase loci NAT1 and NAT2. Pharmacol. Toxicol., 83: 149-157, 1998.
168. Windmill, K. F., McKinnon, R. A., Zhu, X., Gaedigk, A., Grant, D. M., and McManus, M. E. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat. Res., 376: 153-160, 1997.
169. Ilett, K. F., Reeves, P. T., Minchin, R. F., Kinnear, B. F., Watson, H. F., and Kadlubar, F. F. Distribution of acetyltransferase activities in the intestines of rapid and slow acetylator rabbits. Carcinogenesis (Lond.), 12: 1465-1469, 1991.
170. Ware, J. A., and Svensson, C. K. Longitudinal distribution of arylamine A'-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem. Pharmacol., 52: 1613-1620, 1996.
171. Ware, J. A., Reilly, T. P., and Svensson, C. K. Cellular distribution of N-acetyltransferase activity in the rat small intestine. Biochem. Pharmacol., 55: 1475-1479, 1998.
172. Hickman, D., Pope, J., Patil, S. D., Gakis, G., Smelt, V., Stanley, L. A., Payton, M., Unadkat, J. D., and Sim, E. Expression of arylamine N-acetyltransferase in human intestine. Gut, 42: 402-409, 1998.
173. Feng, Y., Wagner, R. J., Fretland, A. J., Becker, W. K., Cooley, A. M., Pretlow, T. P., Lee, K. J., and Hein, D. W. Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2′-dimethyl-4-aminobiphenyl. Cancer Res., 56: 527-531, 1996.
174. Paulsen, J. E., Steffensen, I. L., Namourk, E., Hein, D. W., and Alexander, J. Effect of acetylator genotype on 3,2-dimethyl-4-aminobiphenyl induced aberrant ctypt foci in the colon of hamsters. Carcinogenesis (Lond.), 17: 459-465, 1996.
175. Feng, Y., Fretland, A. J., Rustan, T. D., Jiang, W., Becker, W. K., and Hein, D. W. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol., 147: 56-62, 1997.
176. Purewal, M., Fretland, A. J., Schut, H. A. J., Hein, D. W., and Wargovich, M. J. Association between acetylator genotype and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) DNA adduct formation in colon and prostate of inbred Fischer 344 and Wistar Kyoto rats. Cancer Lett., in press.
177. Ladero, J. M., Fernandez, M. J., Palmeiro, R., Munoz, J. J., Jara, C., Lazaro, C., and Periz-Manga, G. Hepatic acetylator polymorphism in breast cancer patients. Oncology (Basel), 44: 341-344, 1987.
178. Webster, D. J., Flook, D., Jenkins, J., Hutchings, A., and Routledge, P. A. Drug acetylation in breast cancer. Br. J. Cancer, 60: 236-237, 1989.
179. Ilett, K. F., Detchon, P., Ingram D. M., and Castelden, W. M. Acetylation phenotype is not associated with breast cancer. Cancer Res., 30: 6649-6651, 1990.
180. Bulovskaya, L. N., Krupkin, R. G., Bochina, T. A., Shipkova, A. A., and Pavlova, M. V. Acetylator phenotype in patients with breast cancer. Oncology (Basel), 35: 185-188, 1978.
181. Sardas, S., Cok, I., Sardas, O. S., Ilhan, O., and Karakaya, A. E. Polymorphic N-acetylation capacity in breast cancer patients. Int. J. Cancer, 46: 1138-1139, 1990.
182. Philip, P. A., Rogers, H. J., Millis, R. R., Rubens R. D., and Cartwright, R. A. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur. J. Cancer Clin. Oncol., 23: 1701-1706, 1987.
183. Ambrosone, C. B., Freudenheim, J. L., Sinha, R., Graham, S., Marshall, J. R., Vena, J. E., Laughlin, R., Nemota, T., and Shields, P. G. Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms. Int. J. Cancer, 75: 825-830, 1998.
184. Gertig, D. M., Hankinson, S. E., Hough, H., Spiegelman, D., Colditz, G. A., Willett, W. C., Kelsey K. T., and Hunter, D. J. N-Acetyltransferase 2 genotypes, meat intake and breast cancer risk. Int. J. Cancer, 80: 13-17, 1999.
185. Deitz, A. C., Zheng, W., Leff, M. A., Gross, M., Xiao, G-h., Doll, M. A., Wen, W-Q., Folsom, A. R., and Hein, D. W. N-Acetyltransferase-2 (NAT2) acetylation polymorphism, well-done meat intake and breast cancer risk among post-menopausal women. Proc. Am. Assoc. Cancer Res., 40: 148, 1999.
186. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemota, T., Gillenwater, K. A., and Shields, P. G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc., 276: 1494-1501, 1996.
187. Huang, C. S., Chern, H. D., Shen, C. Y., and Chang, K. J. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer, 82: 175-179, 1999.
188. Hunter, D. J., Hankinson, S. E., Hough, H., Gertig, D. A., Garcia-Closas, M., Spiegelman, D., Manson, J. E., Colditz, G. A., Willet, W. C., Speizer, F. E., and Kelsey, K. A prospective study of NAT2 acetylation genotype, cigarette smoking and risk of breast cancer. Carcinogenesis (Lond.), 18: 2127-2132, 1997.
189. Millikan, R. C., Pittman, G. S., Newman, B., Tse, C-K. J., Selmin, O., Rockhill, B., Savitz, D., Moorman, P. G., and Bell, D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 371-378, 1998.
190. Sadrieh, N., Davis, C. D., and Snyderwine, E. G. N-Acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res., 56: 2683-2687, 1996.
191. Stone, E. M., Williams, J. A., Grover, P. L., Gusterson, B. A., and Phillips, D. H. Interindividiaul variation in the metabolic activation of heterocyclic amines and their N-hydroxy derivatives in primary cultures of human mammary epithelial cells. Carcinogenesis (Lond.), 19: 873-879, 1998.
192. Pfau, W., Stone, E. M., Brockstedt, U., Carmicheal, P. L., Marquardt, H., and Phillips, D. H. DNA adducts in human breast tissue: association with N-acetyltransferase-2 (NAT2) and NAT1 genotypes. Cancer Epidemiol. Biomark. Prev., 7: 1019-1025, 1998.
193. Burgess, E. J., and Trafford, J. A. Acetylator phenotype in patients with lung carcinoma: a negative report. Eur. J. Respir. Dis., 67: 17-19, 1985.
194. Roots, I., Drakoulis, N., Ploch, M., Heinemeyer, G., Loddenkemper, R., Minks, T., Nitz, M., Otte, F., and Koch, M. Debrisoquine hydroxylation phenotype, acetylation phenotypes, and ABO blood groups as genetic host factors of lung cancer risk. Klin. Wochenshr., 66 (Suppl XI): 87-97, 1988.
195. Philip, P. A., Fitzgerald, D. L., Cartwright, R. A., Peake, M. D., and Rogers, H. J. Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis (Lond.), 9: 491-493, 1988.
196. Nyberg, F., Hou, S-M., Hemminki, K., Lambert, B., and Pershagen, G. Glutathione S-transferase M1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol. Biomark. Prev., 7: 875-883, 1998.
197. Bouchardy, C., Mitrunen, K., Wikman, H., Husgafvel-Pursiainen, K., Dayer, P., Benhamou, S., and Hirvonen, A. N-Acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics, 8: 291-298, 1998.
198. Hirvonen, A., Pelin, K., Tammilehto, L., Karjalainen, A., Mattson, K., and Linnainmaa, K. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res., 55: 2981-2983, 1995.
199. Hirvonen, A., Saarikoski, S. T., Linnainmaa, K., Loskinen, K., Husgafvel-Puriainen, K., Matttson, K., and Vainio, H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl. Cancer Inst., 88: 1853-1856, 1996.
200. Drozdz, M., Gierek, T., Jesdryczko, A., Pilch, J., and Piekarska, J. N-Acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma (Bratisl.), 34: 481-484, 1987.
201. Gonzalez, M. V., Alvarez, V., Pello, M. F., Menendez, M. J., Suarex, C., and Cota, E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IIB in the susceptibility to head and neck cancer. J. Clin. Pathol., 51: 294-298, 1998.
202. Morita, S., Yano, M., Tasujinaka, T., Ogawa, A., Taniguchi, M., Kaneko, K., Shiozaki, H., Doki, Y., Inoue, M., and Monden, M. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer, 79: 517-520, 1998.
203. Morita, S., Yano, M., Tsujinaka, T., Akiyama, Y., Taniguchi, M., Kaneko, K., Miki, H., Fujii, T., Yoshino, K., Kusuoka, H., and Monden, M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head and neck squamous-cell carcinoma. Int. J. Cancer, 80: 685-688, 1999.
204. Jourenkova-Mironova, N., Wikman, H., Brouchardy, C., Mitrunen, K. Dayer, P., Benhamou, S., and Hirvonen, A. Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics, 9: 533-537, 1999.
205. Katoh, T., Kaneko, S., Boissy, R., Watson, M., Ikemura, K., and Bell, D. A. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis (Lond.), 19: 1803-1807, 1998.
206. Olshan, A., Watson, M. A., Smith, J., Wiessler, M., and Bell, D. A. Association of N-acetyltransferase 1 (NAT1) genotype and smoking with risk of head and neck cancers. Proc. Am. Assoc. Cancer Res., 38: 331, 1997.
207. Agundez, J. A. G., Martinez, C., Olivera, M., Gallardo, L., Ladero, J. M., Rosado, C., Prados, J., Rodriguez-Molina, J., Resel, L., and Benitez, J. Expression in human prostate of drug-and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br. J. Cancer, 78: 1361-1367, 1998.
208. Wadelius, M., Autrup, J. L., Stubbins, M. J., Andersson, S-O., Johansson, J-E., Wadelius, C., Wolf, C. R., Autrup, H., and Rane, A. Polymorphisms in NAT2, CYP2D6, CYP2C19, and GSTP1 and their association with prostate cancer. Pharmacogenetics, 9: 333-340, 1999.
209. Fukutome, K., Watanaba, M., Shiraishi, T., Murata, M., Uemura, H., Kubota, Y., Kawamura, J., Ito, H., and Yatani, R. N-Acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett., 136: 83-87, 1999.
210. Leff, M. A., Epstein, P. N., Doll, M. A., Fretland, A. J., Devanaboyina, U-S., Rustan, R. D., and Hein, D. W. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J. Pharmacol. Exp. Ther., 290: 182-187, 1999.